MVM Life Science Partners — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Urotronicurotronic.comin𝕏Aug 2025 · $80M
Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures.
HealthtechMedical DevicesPlymouth, US
Junfeng Wang(Director)David Perry(Executive Officer, Director)Tan Ching(Director)Hui Hu(Director, Promoter)Lixiao Wang(Director, Promoter)Doug Kohrs(Director)
Co-investorsHM Venture PartnersEnterprise IrelandGilde HealthcareIreland Strategic Investment FundLegend CapitalLightstone Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.